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Monoclonal antibodies directed against the CD20 surface antigen on B cells are widely
used in the therapy of B cell malignancies. Upon administration, the antibodies bind to
CD20 expressing B cells and induce their depletion via cell- and complement-dependent
cytotoxicity or by induction of direct cell killing. The three antibodies currently most often
used in the clinic are Rituximab (RTX), Ofatumumab (OFA) and Obinutuzumab (OBI). Even
though these antibodies are all of the human IgG1 subclass, they have previously been
described to vary considerably in the effector functions involved in therapeutic B cell
depletion, especially in regards to complement activation. Whereas OFA is known to
strongly induce complement-dependent cytotoxicity, OBI is described to be far less
efficient. In contrast, the role of complement in RTX-induced B cell depletion is still under
debate. Some of this dissent might come from the use of different in vitro systems for
characterization of antibody effector functions. We therefore set out to systematically
compare antibody as well as C1q binding and complement-activation by RTX, OFA and
OBI on human B cell lines that differ in expression levels of CD20 and complement-
regulatory proteins as well as human primary B cells. Applying real-time interaction
analysis, we show that the overall strength of C1q binding to live target cells coated
with antibodies positively correlated with the degree of bivalent binding for the antibodies
to CD20. Kinetic analysis revealed that C1q exhibits two binding modes with distinct
affinities and binding stabilities, with exact numbers varying both between antibodies and
cell lines. Furthermore, complement-dependent cell killing by RTX and OBI was highly cell-
line dependent, whereas the superior complement-dependent cytotoxicity by OFA was
independent of the target B cells. All three antibodies were able to initiate deposition of
C3b on the B cell surface, although to varying extent. This suggests that complement
activation occurs but might not necessarily lead to induction of complement-dependent
cytotoxicity. This activation could, however, initiate complement-dependent phagocytosis
as an alternative mechanism of therapeutic B cell depletion.
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Monoclonal antibodies (mAb) applied in the treatment of
malignant diseases employ different immune-mediated
mechanisms that contribute to their efficacy such as antibody-
dependent cellular cytotoxicity (ADCC) (1), antibody-dependent
cellular phagocytosis (ADCP) (2), as well as activation of the
complement system (3). While ADCC and ADCP are accepted as
important mechanisms for successful monoclonal antibody
(mAb) therapy, the importance of the complement system
for mAb therapy is less clear. The Fc-terminus of antibodies
harbors a binding site for the serum protein C1q (4) that
activates the classical complement pathway which, through a
series of proteolytic cleavage events, leads to deposition of the
complement component 3b (C3b) on the surface of opsonized
cells. If sufficient amounts of membrane bound C3b accumulate
on the target cell, eventually pores, called membrane attack
complexes (MAC), are formed by complement proteins C6
through C9 that mediate cell lysis; a process termed as
complement-dependent cytotoxicity (CDC) (3). Moreover,
membrane-bound complement cleavage products such as C3b
or C4b also function as opsonins by interacting with complement
receptors on effector cells which results in complement-
dependent phagocytosis (CDCP) (5). Effective killing of tumor
cells by CDC in vitro has been demonstrated, especially for
certain anti-CD20 antibodies (6–8), but the contribution of
complement to tumor killing in vivo is debated (9–15). To
date, expression of negative regulators of the complement
system (6, 16, 17) and exhaustion of complement components
have been described to limit CDC efficacy in the clinic (11, 18).
Mechanistically, binding of C1q occurs preferably to a
hexameric formation of IgG Fc-tails (19) and it has been shown
that antibodies harboring mutations in the Fc-region that facilitate
this arrangement can induce CDC more efficiently (20, 21).
Depending on their capacity to cluster CD20 on the cell surface,
anti-CD20 antibodies are grouped into type I and type II, the latter
not having this ability (22, 23). Type I antibodies like Rituximab
(RTX) or Ofatumumab (OFA) have been shown to efficiently
activate complement, presumably because clustering facilitates
the formation of hexameric IgG-Fc platforms suitable for C1q
binding (19, 24). Platform formation could also be supported by
type ImAbs acting asmolecular seeds that locally increase antibody
concentration. In contrast, recruitment of the type II mAb
Obinutuzumab (OBI) prevented further binding of mAbs as well
as complement components (25) providing an explanation for its
reduced capacity to activate complement. With respect to their B
cell depleting activity, both type I and type II antibodies are able to
induce ADCC as well as ADCP (23). Type II antibodies are,
however, more efficient at inducing direct cell death (26, 27).
Type I and type II CD20-specific mAbs have also been shown to
differ in their capacity to be internalized following interaction with
FcgRIIb expressed on B cells (28, 29). The underlying molecular
properties for the functional classification into type I and II are still
debated but include the binding epitope (30), the elbow hinge angle
(31, 32), as well as binding orientation (33) and binding stability of
the antibody (34).Frontiers in Immunology | www.frontiersin.org 2Recognition by C1q is the crucial step in activation of the
classical pathway of complement and stronger binding of C1q to
antibody opsonized cells has been correlated with more efficient
target cell lysis (19, 35). However, the parameters involved in the
formation of the optimal antibody platform for C1q binding are
not completely understood yet. Contradicting observations have
especially been made with respect to functionally monovalent
antibodies inducing CDC more efficiently than their
counterparts with bivalent binding capability (19, 36, 37). For
C1q binding to antibody opsonized cells, affinity values in the
low nM range have been reported without resolution of the
kinetic binding parameters (38). Furthermore, the apparent
binding affinity for C1q to monomeric IgG in solution is
around 10 µM (39), whereas the binding to larger, clustered
immune complexes is known to be in the nM range (40).
In a previous study, we analyzed the binding pattern of RTX,
OBI and OFA to Daudi cells by real-time interaction analysis and
showed that OFA displayed the highest degree of bivalent
binding, followed by RTX and then OBI (41). Consequently,
the OFA interaction was less dynamic, i.e. OFA showed a slower
antibody exchange, possibly caused by a higher fraction of
antibodies stabilized by bivalent binding. The degree of
bivalent target engagement thus positively correlates with how
efficiently these mAbs have been shown to induce CDC in vitro.
As the notion that bivalent target engagement is beneficial for
CDC stands in contrast to observations made with antibodies
targeting EGFR (19) and HER2 (37), we set out to develop a real-
time binding assay to investigate C1q capture on live cells
opsonized with CD20 mAbs. We systematically compared
CD20 mAb binding, C1q binding and complement-activation,
as well as C3b deposition that can trigger target cell killing
independently of MAC formation. Several human lymphoma B
cell lines that differ in CD20 expression levels and complement-
regulatory proteins as well as human primary B cells were
included in our analysis to understand the influence of the
model system in the context of complement activation by
CD20 mAbs in vitro. Our data suggests that CD20 specific
mAbs differ in their mode of binding which, in combination
with the type of target cell, determines efficacy of CDC in vitro.MATERIALS AND METHODS
Cell Culture and B Cell Isolation
Ramos (ATCC), Daudi (ATCC), P493.6, LCL1.11 (kindly
provided by Georg Bornkamm, Helmholtz Zentrum, Munich,
Germany) and K562 (kind gift from Dr. Stenerlöw, Uppsala
University) were cultured in a humidified incubator at 37°C with
5% CO2. For interaction analyses, Ramos and K562 cells were
maintained in RPMI 1640 cell medium (Biochrom AG)
supplemented with 10% heat-inactivated FBS (Sigma Life
Science), 2 mM L-glutamine (Biochrom AG) and 100 µg/ml
penicillin-streptomycin (Biochrom AG). Daudi and LCL1.11
cells were cultured in the same medium, but with additional
sodium pyruvate (Sigma-Aldrich) added to a final concentration
of 1 mM. P493.6 cells were cultured in RPMI 1640 withoutJanuary 2021 | Volume 11 | Article 609941
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cells and in addition 0.1 mM MEM non-essential amino acids
(Invitrogen). B cell lines for functional assays were cultured in
RPMI 1640 (Gibco) supplemented with 10% heat-inactivated
FBS (Pan Biotech), 1 mM sodium pyruvate (Gibco), 100 µg/ml
penicillin-streptomycin (C-C-Pro), 2 mM L-glutamine (C-C-
Pro) and 0.1 mM MEM non-essential amino acids (Gibco).
For isolation of human primary B cells, peripheral blood
mononuclear cells were purified from blood cones by density
gradient centrifugation. PBMCs were then subjected to
MojoSort™ Human B Cell Isolation Kit (BioLegend) according
to the manufacturer´s instructions. Healthy human and CLL
patient PBMCs were isolated from peripheral blood by density
gradient centrifugation and either used immediately or stored at
−80°C in FBS containing 10% DMSO until usage.
Seeding for LigandTracer analysis
Cells were immobilized either on petri dishes (Nunc 263991,
ThermoFisher Scientific) or LigandTracer MultiDishes 2x2
(Ridgeview Instruments) for real-time binding assays,
essentially as previously published (42). In brief, a
biomolecular anchor molecule (BAM) (SUNBRIGHT® OE-
040CS, NOF Corporation) was dissolved to 2 mg/ml in ddH2O
water and circular drops of 400 µl were carefully placed onto the
dishes and incubated for 1 h at room temperature. After carefully
aspirating the BAM solution, cells suspended in PBS (due to
differences in size 7.5*106 cells/ml for Ramos, Daudi, P493.6 and
LCL1.11, 2.5*106 cells/ml for K562) were placed onto the BAM
coated spots. Human primary B cells were resuspended in
RPMI 1640 (supplemented with 1 mM sodium pyruvate,
100 µg/ml penicillin-streptomycin, 2 mM L-glutamine and
100 µM MEM non-essential amino acids) and 2*106 cells and
seeded on BAM coated spots. Cells were then incubated for
40 min at room temperature. Cells that did not attach were
carefully removed and cell culture medium was added. Seeded
cells were kept a humidified incubator at 37°C with 5% CO2 and
used for experiments the next day.
Antibodies and Protein Labeling
For real-time experiments Rituximab and Ofatumumab were
purchased from Apoteket AB (Sweden) in clinical formulation,
Rituximab and Ofatumumab for functional experiments, as well
as Obinutuzumab were purchased from the pharmacy of the
university hospital of Schleswig-Holstein (Kiel, Germany). Fab
fragments were generated using the Pierce Fab Preparation Kit
(Thermo Fisher Scientific) following the manufacturer’s
instructions, which essentially comprised enzymatic digestion
with papain followed by removal of the Fc-part via a protein A
column. Fab fragmentation was verified by running a non-
reducing SDS-PAGE with subsequent Coomassie staining
(Supplementary Figure 1). After Fab fragmentation, a buffer
exchange to either PBS or borate buffer pH 9.2 (the latter if the
Fab was to be labeled fluorescently) was performed using a Nap-
5 Sephadex G-25 column (Illustra, GE Healthcare). Antibodies
were diluted to 2 mg/ml in PBS and mixed with borate buffer
pH 9.2 in 1:2 volume ratio for fluorescent labeling. FluoresceinFrontiers in Immunology | www.frontiersin.org 3isothiocyanate (FITC) was dissolved in DMSO and 100 ng FITC
was added for every µg protein. After incubation at 37°C for
90 min, unconjugated FITC was removed by purification
through a Nap-5 column (Illustra, GE Healthcare). Labeled
antibodies and Fab fragments were kept at 4°C for short term
and at −20°C for long storage. For labeling, human complement
component C1q (Merck Millipore) was mixed 5:1 with 0.2 M
sodium bicarbonate buffer pH 9. Atto488 was dissolved in
DMSO and 0.5 µg for every µg protein was added and
incubated for 1 h at room temperature. Excess fluorophore was
removed through a Nap-5 column and C1q was stored at 4°C
overnight and always used for experiments the following day.
Protein concentrations after labeling were measured with
NanoPhotometer (Implen P360). For C1q a molar extinction
coefficient of 2.742*105 cm−1M−1 was used.
Real-Time Cell-Binding Assay
LigandTracer Green (Ridgeview Instruments) was used to study
molecular interactions on live cells. The instrument consists of
an inclined cell dish holder that rotates during the measurement
and a fluorescent detector mounted that records signals from the
upper position of the cell dish, thereby avoiding fluorescence
from the bulk liquid containing unbound ligand. For binding
experiments with labeled antibodies or Fab fragments, at least
two positions were measured during each rotation: CD20
expressing cells (Ramos, Daudi, P493.6, LCL1.11 or primary B
cells) in the target position and K562 cells that lack CD20 or
media only as control for subtraction of background
fluorescence. Each full rotation takes 70 s and results in at least
one background subtracted data point. Experiments were
performed with the cell culture medium used for culturing the
CD20 expressing cells. After recording a baseline, FITC-labeled
protein was added to initiate the association phase. After
recording an association phase, the incubation media was
changed to either plain media not containing any ligand or
media containing unlabeled ligand to monitor dissociation.
For binding experiments with labeled C1q and unlabeled
antibodies, four positions were measured during each rotation
with each half of the MultiDish 2x2 containing one spot of CD20
expressing cells and one spot with K562 cells for background
correction, resulting in two background corrected binding curves
with a data collection frequency of 0.86 min-1. Cells were pre-
incubated with unlabeled antibody in CO2 independent RPMI
medium at room temperature at a concentration and time that
allowed for binding to reach equilibrium. This incubation
solution was used as running buffer for LigandTracer
experiments with C1q and, after recording a baseline, labeled
C1q was added in three increasing concentrations (1.4 nM,
3.9 nM and 9.6 nM) for the association phase. For the
dissociation phase, the incubation solution was exchanged to
the same media containing unlabeled antibody to keep the
antibody concentration constant during the entire experiment.
Real-Time Interaction Analysis
Real-time binding data for antibodies and Fab fragments was
analyzed with TraceDrawer 1.9 (Ridgeview Instruments)January 2021 | Volume 11 | Article 609941
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assumes that a reversible binding process between a ligand (L)
and a target (T) receptor is characterized by a single association
rate constant ka and dissociation rate constant kd (Eq. 1) also










The interaction half-life t1/2, i.e. the time until half of the






In real-time interaction analysis, the kinetic parameters are
extracted from the non-linearity of the binding signal, B, over
time which needs to be proportional to the number of ligand-
target complexes formed (Eq. 4).
dB
d t= = ka · ½L · (Bmax − B) − kd · B ½4
For this type of analysis, the number of targets needs to stay
constant during the experiment and, in contrast to end-point
measurements, target saturation is not required. Besides the
interaction rate constants, also the theoretical signal at target
saturation Bmax is estimated from the binding curve.
Real-time binding data for C1q to antibody opsonized cells
was also evaluated with InteractionMap (IM). This analysis
searches for 1:1-like interactions in a defined ka and kd
parameter space that correspond to the measured binding data




j=1½Wij*CurveComponent(conc, kia, kjd) ½5
Each interaction is depicted in an on-off plot and colors are
assigned according the weighing factors Wij: the more an
individual interaction contributes to the measured curve, the
warmer the color.
Human Samples
Human serum samples and peripheral blood for CDC assays
were collected from healthy individuals with approved consent.
Blood cones used to isolate B cells for interaction analysis were
provided by the Department of Transfusion Medicine and
Haemostaseology of the University Clinics Erlangen, Germany,
with informed consent of the donor and the local ethical
committee. PBMC from CLL patients were provided by the
Department of Medicine II, Kiel, Germany with informed
consent of the donors.Frontiers in Immunology | www.frontiersin.org 4Complement Dependent Cytotoxicity
(CDC) Assay
For analysis of CDC induction and complement C3b deposition
5*104 Ramos, Daudi, P493.6 or LCL1.11 cells or 7.5*105 human
PBMCs were resuspended in RPMI 1640 supplemented with
10% FBS, 100 µg/ml penicillin-streptomycin, 2 mM L-glutamine,
1 mM sodium pyruvate and 0.1 mM MEM non-essential amino
acids. CD20-specific antibodies (OFA, RTX, or OBI) were added
at either 20 µg/ml or 2 µg/ml. Human serum was obtained, stored
at −20°C and added to 20% of the reaction volume. Controls
included serum heat inactivated at 56°C for 30 min or cells
incubated with serum/heat-inactivated serum but no CD20-
specific antibodies. Cells were then incubated for 30 min
at 37°C. The reaction was stopped by addition of ice-cold PBS
supplemented with 10% FBS and 0.05% sodium azide. Cells were
then stained with DAPI and anti-C3b-FITC (clone 2C6,
Cedarlane) for subsequent flow cytometry analysis. Human
primary cells were in addition stained with anti-CD19-PE/
Cyanine7 (clone HIB19, Biolegend) to label B cells. Samples
were acquired on a FACSCantoII (BD Biosciences) and analyzed
using FACSDiva and FlowJo Software.
Flow Cytometric Analysis
Expression of B cell surface markers was performed by flow
cytometry. 1*105 cells (B cell lines or human primary B cells)
were stained with anti-CD19-PE/Cyanine7 (clone HIB19,
BioLegend), anti-CD20-Alexa647 (Rituximab, labeled with
ThermoFisher AlexaFluor647 Labeling Kit), anti-FcgRIIb-
Alexa647 (clone 2B6, labeled with ThermoFisher AlexaFluor647
Labeling Kit), anti-CD55-PerCP/Cyanine5.5 (clone JS11,
BioLegend) or anti-CD59-PE (clone H19, BioLegend). Dead cells
were excluded by subsequent staining with DAPI. Samples were
acquired on a FACSCantoII (BD Biosciences) and analyzed using
FACSDiva and FlowJo Software.
C1q Binding ELISA
Interaction of CD20-specific mAbs with C1q was analyzed by
enzyme-linked immunosorbent assay (ELISA). All incubation
steps were performed at room temperature for 1 h. 100 µg/ml of
mAbs were coated in 50 mM sodium bicarbonate buffer pH 9.6
(Sigma). After three washing steps with PBS 200 µl of blocking
buffer (PBS containing 3% bovine serum albumin and 0.05%
Tween-20) were added. After removal of blocking buffer
increasing concentrations of native human C1q (Serotec)
diluted in blocking buffer were added followed by three more
washing steps. HRP-conjugated sheep anti human complement
C1q (Serotec) was diluted 1:500 in blocking buffer. Plates were
washed three times with PBS and TMB solution (Invitrogen) was
added to detect anti-C1q-HRP. The reaction was stopped with
6% orthophosphoric acid.
Quantification of GM1 Levels
Human B cells (Ramos, Daudi, P493.6, LCL1.11) or human
peripheral blood leukocytes were incubated with AlexaFluor555-
labeled cholera toxin subunit B (CT-B; ThermoFisher Scientific)
diluted in RPMI 1640 medium for 10 min at 4°C. Bound CT-BJanuary 2021 | Volume 11 | Article 609941
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CT-B, rabbit serum; ThermoFisher Scientific) for 15 min at 4°C
and GM1 levels were detected by flow cytometry on a
FACSCytoFLEX S (Beckman Coulter Life Sciences). Human
peripheral blood leukocytes were purified by RBC lysis
and stained with anti-CD19-PE/Cyanine7 (clone HIB19;
BioLegend) to detect GM1 levels on primary B cells. Data was
analyzed with Flow Cytometry Analysis Software (FlowJo).
Statistics
GraphPad Prism v8.3 was used for statistical analysis. Initially,
shapiro-wilk test was used to determine Gaussian distribution of
data sets. Subsequently, Kruskal-Wallis and Dunn´s multipleFrontiers in Immunology | www.frontiersin.org 5comparisons test (non-Gaussian distribution) or analysis of
variance (ANOVA) followed by Sidak´s multiple comparisons
post hoc test (Gaussian distribution) were performed.
Alternatively, two-way RM ANOVA and multiple comparisons
tests were applied. A detailed description of statistical tests used
for individual experiments can be found in the respective
figure legends.RESULTS
A variety of B cell lines such as Raji (11, 23, 38, 43, 44), Ramos




FIGURE 1 | Binding stability of CD20 mAbs to human lymphoma B cell lines. Binding of 60 nM Ofatumumab (OFA), Rituximab (RTX), or Obinutuzumab (OBI) to
Daudi (A), Ramos (B), LCL1.11 (C), or P493.6 (D) cells was recorded until equilibrium was approached (not shown) followed by measurement of mAb dissociation
either in plain cell culture medium or in presence of 60 nM of the respective unlabeled (unlab.) antibody. For all cell lines the dissociation of OFA was measured in
presence of 180 nM unlabeled OFA (instead of 60 nM) to enhance possible cell-line differences. (E) Signal intensities were normalized to 100% at the beginning of
the dissociation. The remaining signal after 1 h (black) and 2 h (gray) dissociation both in plain media (solid) and in presence of unlabeled antibody (shaded) are
plotted for human B cell lines.January 2021 | Volume 11 | Article 609941
Bondza et al. Complement Activation by CD20 mAbscytotoxic IgG activity directed against CD20. When studying the
interaction of CD20-specific mAbs, we previously found that
binding to the Burkitt lymphoma cell line Daudi (47) is most
stable forOFA, followed byRTX and least stable for OBI, due to the
mAbs engaging in bivalent target binding to differing degrees (41).
To extend our analyses, we evaluated the binding pattern of the
three mAbs by real-time interaction analysis on additional human
lymphoma B cell lines (the Burkitt lymphoma cell line Ramos (48)
and the lymphoblastoid cell lines P493.6 (49) and LCL1.11)
(Figures 1A–D), as well as primary human B cells (Figure 2A)
purified from human peripheral blood (Supplementary Figure 2).
Consistent with our previous data, OFA binding is most stable,
followed by RTX, whereas OBI displayed the least stable binding
(Figures 1E and 2B). Also, in linewith previous results, the number
of cell-boundOFAmoleculeswas barely influenced by the presence
offreemAb in solution,whereas thenumber of cell-boundRTXand
OBI molecules was clearly decreased by the presence of unbound
mAb during the dissociation phase, implying more dynamic
interactions, both on cell lines and on primary human B cells.
Compared toRTX, the stability of boundOBI is evenmore strongly
affected by the presence offree antibody in solution on all tested cell
lines (Figure 1E), however this difference was less pronounced on
primary human B cells (Figure 2B).
While confirming that the overall binding pattern of the CD20
mAbs is consistent across the tested cell lines as well as on primary
human B cells, we also noticed differences in binding stability
between the cell lines. On Ramos cells, RTX displayed most stable
binding whereas the other three cell lines showed very similar
dissociation patterns in plain cell culturemedium (Figure 3A, solid
lines). In the presence of free antibody in solution, the apparent off-
rate for RTX was slowest for the dissociation from Ramos cells,
followed by LCL1.11 cells, then P493.6 cells and lastly Daudi
cells with the fastest apparent off-rate (Figure 3A, dashed
lines, Supplementary Table 1). The stability of bound RTX
further decreased with increasing concentrations for all cell linesFrontiers in Immunology | www.frontiersin.org 6(Figure 3B), with the half-life of bound RTX in the presence of free
antibody in solution at 60 nM being roughly half compared to the
half-life at 10nMacross all tested cell lines (Table1). Incontrast, the
dissociation of RTX-Fab was neither influenced by the Fab
concentration, nor by the presence of free ligand in solution
(Figures 3C, D), which is a good indication for the interaction
following a 1:1 behavior.Moreover, the stability of bound RTX-Fab
did not significantly differ between the cell lines (Figure 3D and
Supplementary Table 2), indicating that the differences in binding
stability forRTX-IgGaredue to secondary stabilizingeffects, suchas
e.g. bivalency or Fc-interactions.
For OBI, the apparent off-rate as measured in plain medium
was slowest for the dissociation from Ramos cells, followed by
P493.6, LCL1.11 and lastly Daudi cells with the fastest apparent
off-rate (Figure 3E, solid lines). This order changed when the
stability of cell-bound OBI was studied in the presence of
unlabeled antibody in solution: after 2 h the highest percentage
of remaining OBI molecules was on P493.6 cells, followed by
LCL1.11, Ramos and lastly Daudi cells (Figure 3E, dashed lines).
In agreement with previously obtained data (41), the binding
stability of OFA was not significantly influenced by the presence
of equimolar amounts of free antibody in the 10-60 nM range
(data not shown). Therefore, the stability of OFA was tested with
60 nM labeled antibody during the association, followed by
three-fold molar excess of unlabeled antibody during the
dissociation phase. OFA dissociated slowest from LCL1.11
cells, followed by Ramos and P493.6 cells and lastly Daudi cells
with the fastest apparent off-rate (Figures 3F, G). Fitting a single
exponential decay to the dissociation phase resulted in average
half-lives of 26.7 h for LCL1.11, 17.8 h for Ramos, 12.2 h for
P493.6 and 9.9 h for Daudi cells. For all three mAbs, both in
absence and presence of unlabeled antibody, the apparent off-
rate was fastest from Daudi cells.
The off-rate, which is a measure for the binding stability, as
well as bivalent target engagement of mAbs have been discussedA B
FIGURE 2 | Binding stability of CD20 mAbs to human primary B cells. Binding of 60 nM Ofatumumab (OFA), Rituximab (RTX) or Obinutuzumab (OBI) to primary
human B cells isolated from blood of healthy donors was recorded until equilibrium was approached (not shown) and then mAb dissociation was measured either in
plain cell culture medium or in presence of 60 nM of the respective unlabeled antibody. (A) One out of three independent measurements shown. (B) Signal intensities
were normalized to 100% at the beginning of the dissociation. The remaining signal after 1 h (black) and 2 h (gray) dissociation both in plain media (solid) and in
presence of unlabeled antibody (shaded) are plotted. Bars show mean ± standard deviation of n=3 experiments using cells from different donors. For statistical
analysis of signal intensities in plain media and in presence of unlabeled antibody for individual time points, two-way ANOVA and Tukey´s multiple comparison test
were applied. *p<0.05, n.s. not significant.January 2021 | Volume 11 | Article 609941
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complement activation. We therefore set-up an assay to
monitor C1q binding in real-time on living cells opsonized
with CD20 antibodies to establish the kinetics of the C1q
interaction. Binding to cells coated with either RTX or OFA
clearly deviated from a 1:1 interaction which can be directly seen
from the dissociation phase of the binding curves where a
fraction of C1q quickly releases from the opsonized cells,
whereas another fraction of C1q is more stably bound (Figures
4A, B). Data was evaluated with InteractionMap that depicts theFrontiers in Immunology | www.frontiersin.org 7number of 1:1-like interactions contributing to the overall
binding pattern in an on-off plot. This type of analysis resulted
in discovery of two distinct interaction components for all cell
lines. These components primarily differed in their off-rates,
which reflects the binding stability. The interaction of C1q to
cells coated with OFA (Figure 4B) resulted in an over-all
stronger and more stable interaction compared to cells coated
with RTX (Figure 4A), whereas C1q binding to cells coated with
OBI was too weak to give a clear signal above background





FIGURE 3 | Binding stability of CD20 mAbs across different lymphoma B cell lines. (A) Dissociation after incubation with 60 nM fluorescein isothiocyanate Rituximab
(FITC-RTX) in either plain medium (solid lines) or in the presence of 60 nM unlabeled RTX (dashed lines). (B) Dissociation after incubation with 10 nM, 30 nM or
60 nM FITC-RTX in the presence of equimolar amounts of unlabeled RTX. (C) Dissociation in plain medium after incubation with either 10 nM (dashed lines) or 60 nM
(solid lines) FITC-RTX-Fab. (D) Dissociation after incubation with 60 nM FITC-RTX-Fab in either plain medium (solid lines) or presence of 60 nM unlabeled RTX-Fab
(dashed lines). (E) Dissociation after incubation with 60 nM FITC-Obinutuzumab (OBI) in either plain medium (solid lines) or in the presence of 60 nM unlabeled OBI
(dashed lines). (F) Dissociation after incubation with 60 nM FITC-Ofatumumab (OFA) in the presence of 180 nM unlabeled OFA. Note the different y-axis scaling.
(G) Average half-life for bound OFA calculated from data shown in (F). Bars represent mean ± standard deviation of n=3–4 independent measurements.January 2021 | Volume 11 | Article 609941
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linked immunosorbent assay (ELISA), emphasizing the
importance of a cellular model system for complex binding
studies (Supplementary Figure 4).
Interaction analysis of C1q with Rituximab opsonized Daudi
cells revealed affinity values in the range of 0.8-2.3 nM for the
strong interaction and 32-70 nM for the weak interaction
depending on the cell line (Table 2). The kd value differed by
more than 100-fold between the two interactions, resulting in
half-lives above 2 h for the stable interaction (Figure 4C, peaks
toward the left on the InteractionMaps) and 1-2 min for the
transient interaction (Figure 4C, peaks toward the right on the
InteractionMaps). For all cell-lines the strong interaction
component contributed less to overall C1q binding, with an
estimated strong binding site fraction of 0.13 for Daudi, 0.15 for
Ramos 0.17 for LCL1.11 and 0.20 for P493.6 cells at the tested
C1q concentrations (Figure 4C). The half-life for strongly bound
C1q molecules was longest on LCL1.11 cells, followed by Ramos
and P493.6 cells, whereas C1q displayed the shortest half-life on
RTX-opsonized Daudi cells. Taking both half-life and fraction of
binding sites into account, C1q binding was clearly least stable on
Daudi cells, which corresponds with RTX also displaying least
stable binding to these cells.
Depending on the cell line, the interaction with OFA
opsonized cells resulted in affinities of 0.07-0.2 nM for the
stable component and 5-20 nM for the weaker binding
component. Half-lives for the weak C1q binding component
were 1-3 min on OFA opsonized cells and thus very similar to
those observed for the weak binding component on RTX
opsonized cells. Half-lives for the strong C1q binding
component were longer for OFA opsonized cells than for RTX
opsonized cells. Concerning the cell-lines incubated with OFA,
the half-life for strongly bound C1q was shortest on Daudi cells
(9.3 h), followed by LCL1.11 cells (10.8 h) and very similar on
Ramos and P493.6 cells (both 11.6 h) (Table 2). The fraction of
strong C1q binding sites was similar on OFA-opsonized Daudi
and P493.6 cells with 0.42 and 0.43 respectively, whereas it was
higher with 0.77 for OFA-opsonized Ramos and highest on
LCL1.11 cells with 0.85, which correlates with the OFA
binding stability on these cell lines. Overall differences in C1q
binding strength were more pronounced when comparing RTX
and OFA than the differences between the cell lines.Frontiers in Immunology | www.frontiersin.org 8Next, we analyzed the expression of selected cell surface
proteins that might influence antibody binding stability and
complement activation on these cell lines, as well as on
primary human B cells to see if these could explain the
observed differences (Figure 5). While Ramos and Daudi cells
expressed CD20 to comparable degrees as primary B cells, CD20
expression on LCL1.11 cells was very low. In contrast to the other
cell lines, P493.6 cells showed variable but elevated expression
levels of CD20 and additionally high levels of inhibitory FcgRIIb
that can potentially interact with the Fc portion of the antibodies
(28). Daudi cells expressed FcgRIIb to comparable levels as
primary B cells, whereas expression was higher on LCL1.11
cells and absent on Ramos cells. Consequently, a direct
correlation for expression levels of CD20 and FcgRIIb did not
become apparent in regards to antibody binding stability and
subsequent C1q capture. The expression of the complement
regulatory proteins CD55, an inhibitor of C3 and C5
convertases on the cell surface (50), and CD59 which blocks
MAC formation (51) was also analyzed as these might have an
impact on how C1q capture translates to complement activation.
We found that CD55 expression was highest on P493.6 cells,
LCL1.11 and primary B cells. CD59 expression was elevated on
P493.6 and LCL1.11 cells in comparison to primary B cells. In
contrast, Daudi and Ramos cells expressed only low levels or
even completely lacked CD55 and CD59 confirming previous
reports (52).
Given the remarkable differences observed for the lymphoma
cell lines, we subsequently assessed the functional consequences
of distinct CD20, CD55 and CD59 expression for induction of
complement-dependent cell lysis (CDC) induced by the different
CD20-specific IgG (Figure 6). Upon addition of surface-
saturating doses of OFA (20µg/ml) normal human serum
(NHS) was able to significantly induce cell death in all cell
lines tested (Figure 6A, Supplementary Figure 5). At this
dose, even OBI mediated CDC in Ramos and Daudi cells and
RTX was in addition able to kill P493.6 cells. At lower antibody
doses, CDC induction was overall decreased. Still, OFA retained
its superior capacity to induce complement-dependent cell
death, followed by RTX, while OBI was hardly able to induce
CDC anymore (Figure 6B, Supplementary Figure 6). Of note,
differences between the cell lines were not restricted to CDC
induction. As OBI has previously been described to induce
apoptosis (26) we also assessed the capacity of CD20-specific
mAbs to induce direct killing of B cells. Indeed, following
incubation of cells with anti-CD20 mAbs in absence of serum
enhanced cell killing could only be observed for high-dose OBI
treatment but was also restricted to P493.6 and LCL1.11 cells
(Supplementary Figures 7A, B), the cell lines showing the
highest or lowest CD20 expression levels, respectively. This
suggests that other factors beyond CD20 expression are
involved in this killing mechanism. In contrast to assays with
human lymphoma cell lines where successful initiation of CDC
resulted in an increase of DAPI+ cells, it was not possible to
detect dead B cells in primary human samples. Instead, primary
B cells seemed to disintegrate during the incubation time. We
therefore quantified living, i.e. DAPI-, B cells instead andTABLE 1 | Rituximab (RTX) binding stability at 10 nM and 60 nM was studied in
the presence of unlabeled mAb in solution.




Ramos 10 nM 3.32E-05 348
60 nM 7.54E-05 153 0.44
Daudi 10 nM 7.17E-05 161
60 nM 1.28E-04 90 0.56
P493.6 10 nM 4.97E-05 232
60 nM 1.03E-04 112 0.48
LCL1.11 10 nM 5.14E-05 225
60 nM 9.69E-05 119 0.53The first 2 h of dissociation were used to calculate dissociation rate constants and
corresponding half-lives.January 2021 | Volume 11 | Article 609941
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C
FIGURE 4 | Binding of C1q to antibody opsonized B cells. Binding of fluorescent C1q to mAb opsonized Ramos (orange), Daudi (blue), P493.6 (black) and LCL1.11
cells (green) at concentrations of 1.4 nM, 3.9 nM, and 9.6 nM followed by dissociation. Cells were pre-incubated with either 60 nM unlabeled Rituximab (RTX) (A) or
Ofatumumab (OFA) (B) for 1 h at room temperature prior to C1q binding and the antibody concentration was kept constant during the entire experiment.
(C) InteractionMap for C1q binding to mAb opsonized cells. InteractionMap (IM) is an on/off-plot with each pixel representing a unique ka/kd combination and heat-
map coloration indicating how much each combination is contributing to the interaction analyzed. Per cell line n=3–4 replicates were calculated into one IM.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6099419
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in the presence of human serum (Figures 7A, B). With respect to
direct cell killing by the mAbs, a non-significant reduction in
viable B cells could be observed upon OBI addition
(Supplementary Figure 7C).
Induction of CDC is the ultimate result of complement
activation. One crucial step during the activation cascade is,
however, deposition of complement C3 on the cell surface. In
addition to its role in advancing the activation cascade the
cleavage product C3b also poses as a ligand for complement
receptors expressed on phagocytic cells thereby marking target
cells for complement-dependent phagocytosis (CDCP) (5).
Given that CDCP might therefore also be involved in
complement-dependent effector functions of cytotoxic IgG in
vivo, we also investigated deposition of C3b (and its inactivated
form iC3b) upon treatment of B cells with anti-CD20 IgG. C3b
could only be observed upon addition of anti-CD20 IgG and
normal human serum, but not heat-inactivated serum (Figures
6C, D, and 7C), and C3b levels were highest on P493.6 cells but
surprisingly low on Ramos, Daudi and LCL1.11 cells. Potentially,
sufficient complement activation (including C3b deposition)
triggers lysis of cells so that C3b on these cells can no longer
be detected. Consequently, only cells that are not killed by the
complement system would still show elevated C3b levels. This
might also explain higher C3b detection upon treatment with the
lower antibody dose (Figure 6D) and the minor C3b deposition
on primary human B cells (Figure 7C). Even though
complement activation in this scenario might be insufficient to
trigger direct cell killing via MAC formation one cannot exclude
that the deposited C3b would be able to induce phagocytosis and
thus contribute to target cell killing.
CD20-specific antibodies are used to treat a variety of B cell
malignancies, however for chronic lymphocytic leukemia (CLL)
a reduced therapeutic potential has been observed (52). This was
previously attributed to the fact that CLL B cells have been shownFrontiers in Immunology | www.frontiersin.org 10to express lower levels of CD20 (53–55) that might in turn reduce
effector functions by anti-CD20 IgG, especially those dependent
on complement activation (56). Given that we noticed CD20
expression levels to not be the sole factor determining efficacy of
complement activation we compared B cells from 9 different CLL
patients with respect to B cell surface marker expression (Figure
8A). As previously described, CD20 was expressed at lower levels
on most CLL B cell samples however two of the donors did show
elevated expression. In comparison to B cells from healthy
donors, CLL B cells were characterized by homogenous
decreased CD55 expression. In contrast, CD59 expression
varied largely between donors but was overall increased. This
suggests a reduced susceptibility toward MAC formation and
therefore CDC but potentially an accumulation of active C3b on
the B cell surface. Within the CLL patient cohort we identified
three samples with different profiles regarding CD20 and CD59
that were further submitted to our CDC assay. Upon treatment
with anti-CD20 IgG and human serum, CD20 turned out to be
the more prominent determinant of complement-induced
cytotoxicity as the strongest reduction of living B cells
(CD19+DAPI-) by OFA was observed in the CD20++ sample.
For this donor, RTX also caused a significant decrease in
presence of NHS in comparison to HIS while no differences
could be observed for OBI (Figures 8B, C). In addition, OFA and
RTX, but not OBI, induced significant deposition of complement
C3b (Figure 8D). Lower CD20 expression in the second and
third CLL sample was associated with dampened OFA and
abrogated RTX induced reduction of living B cells, irrespective
of the CD59 expression level (Figures 8B, C). Surprisingly, we
observed an increase in CD19-DAPI- cells consistently upon
treatment of CLL cells with OBI (Figure 8B, Supplementary
Figure 8). Independent of cell killing this suggests that OBI
might be able to induce CD19 loss on B cells as has previously
only been described for RTX (57, 58). Accordingly, an increase of
CD19- cells could also be noticed upon RTX addition for theTABLE 2 | Kinetic values for C1q interaction components on mAb opsonized cells as extracted by global InteractionMap analysis for each condition.
Strong interaction component
ka1 (1/(M*s)) kd1 (1/s) KD1 (M) half-life (min) fraction binding sites
RTX-Ramos 5.2E+04 4.8E-05 9.3E-10 240 0.15
RTX-Daudi 3.4E+04 7.8E-05 2.3E-09 147 0.13
RTX-P493.6 6.7E+04 5.6E-05 8.3E-10 208 0.20
RTX-LCL1.11 3.4E+04 4.0E-05 1.2E-09 286 0.17
OFA-Ramos 2.3E+05 1.7E-05 7.1E-11 694 0.77
OFA-Daudi 1.1E+05 2.1E-05 1.9E-10 558 0.42
OFA-P493.6 1.5E+05 1.7E-05 1.1E-10 700 0.43
OFA-LCL1.11 7.6E+04 1.8E-05 2.4E-10 649 0.85
Weak interaction component
ka2 (1/(M*s)) kd2 (1/s) KD2 (M) half-life (min) fraction binding sites
RTX-Ramos 2.0E+05 1.4E-02 7.0E-08 1 0.85
RTX-Daudi 1.8E+05 9.1E-03 4.9E-08 1 0.87
RTX-P493.6 2.1E+05 6.7E-03 3.2E-08 2 0.80
RTX-LCL1.11 1.5E+05 9.8E-03 6.4E-08 1 0.83
OFA-Ramos 1.0E+06 5.3E-03 5.1E-09 2 0.23
OFA-Daudi 6.1E+05 8.8E-03 1.4E-08 1 0.58
OFA-P493.6 4.5E+05 8.8E-03 2.0E-08 1 0.57
OFA-LCL1.11 5.7E+05 4.3E-03 7.6E-09 3 0.15January 2021 | Volume 11 | Article 609941
Bondza et al. Complement Activation by CD20 mAbsCD20++ CLL sample (Figure 8B, Supplementary Figure 8). Of
note, CLL PBMC samples were stored frozen before the assay. To
exclude an impact of freezing on susceptibility for CDC we also
performed the assays with healthy human PBMCs following
frozen storage (Supplementary Figure 9). Indeed, cells
previously frozen were much more sensitive toward anti-CD20
mAb induced CDC as OFA, RTX and even OBI caused
significant cell death and C3b deposition not observed with
fresh PBMCs.DISCUSSION
By applying real-time interaction analysis, we have previously
shown that the stability of bound mAbs relates to the fraction of
molecules that engage in bivalent binding. Accordingly, the
highest fraction of bivalently bound antibody and the least
dynamic binding pattern can be seen for OFA, while OBI
displays the most dynamic pattern least stabilized by bivalency.
Even though the present study confirmed these observations for
additional B cell lines as well as primary B cells, we also observedFrontiers in Immunology | www.frontiersin.org 11that binding stability of anti-CD20 IgGs varies between human B
cell lines. For instance, the stability of RTX in the presence of
unlabeled mAb in solution was roughly two-fold less on Daudi
compared to Ramos cells during the first hour of dissociation
while primary human B cells displayed less variation with
apparent off-rates for RTX being similar to those observed on
Daudi cells. Differences between cell types were, however,
smaller than differences between the antibodies, with e.g. OFA
having a 10-fold longer binding half-life than RTX on
Daudi cells.
These differences further translate to specific kinetics of C1q
capture by antibody opsonized cells: Whereas the overall binding
stability of C1q seems to correlate with OFA binding stability,
C1q binding to RTX-opsonized cells was overall quite similar,
except for RTX-opsonized Daudi cells that exhibited the weakest
C1q capture and in line with this also least stable RTX binding.
Binding of C1q to OFA opsonized cells was thus clearly stronger
than for RTX on all tested cell lines, whereas binding of C1q to
OBI opsonized cells could not be detected. Bivalent target
engagement therefore positively correlates with strong C1q
capture for the investigated anti-CD20 IgGs and expandingFIGURE 5 | Comparison of surface marker expression. Expression of CD20, inhibitory FcgRIIb and complement-regulatory proteins CD55 and CD59 was assessed
by flow cytometry on various B cell lines in comparison to primary human peripheral blood B cells from healthy donors. Symbols indicate biological replicates of the
median fluorescence intensity (MFI) of the respective marker. Bars show statistical mean. Kruskal-Wallis test and Dunn´s multiple comparisons post-hoc test were
applied to calculate statistical significance. *p<0.05, **p<0.01, ****p<0.0001.January 2021 | Volume 11 | Article 609941
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interest, as contrasting observations have been made for other
antigens (19, 37). The real-time binding assay presented in this
study also allowed to resolve the presence of two interactions, as
well as their kinetic and affinity values for C1q binding to anti-
CD20 IgG opsonized cells. The two interactions differed mainly
with respect to their dissociation rate constant kd, indicating that
one fraction of C1q molecules is bound noticeably more stable
than the remaining fraction. The interaction peaks of both C1q
binding components as displayed in InteractionMaps were
elongated in the y-axis direction, indicating heterogeneity inFrontiers in Immunology | www.frontiersin.org 12how C1q recognizes its binding partners, which is a sign of
multivalent target engagement. As InteractionMap assumes that
a binding curve can be explained by the weighted sum of
individual 1:1 binding curves, multivalent binding becomes
visible as a poorly defined ka value that is seemingly changing
during the interaction. This is due to the ratio of unbound
receptors versus bound receptors decreasing faster than
predicted as one ligand binds multiple targets, causing the rate
of ligand-target complex formation to slow down more than
what is expected according to a 1:1 model. This is especially




FIGURE 6 | Complement dependent lysis and C3b deposition on B cell lines. Ramos, Daudi, P493.6 and LCL1.11 B cell lines were treated with 20 µg/ml (A, C) or
2 µg/ml (B, D) anti-CD20 mAb and 20% human serum (white bars) for 30 min at 37°C. As controls, cells were treated with heat-inactivated serum (black bars) or
with serum in absence of anti-CD20 mAb. (A, B) Dead cells were quantified by flow cytometry analysis of DAPI stained cells. (C, D) Quantification of C3b/iC3b
deposition on B cells. Bars show statistical mean ± standard deviation of n=3–5 independent experiments each using three to seven human serum samples (A, C)
or n=2–3 independent experiments each using three to four human serum samples (B, D) per cell line. For statistical analysis, two-way ANOVA and Tukey´s multiple
comparison test were applied. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.January 2021 | Volume 11 | Article 609941
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OFA-opsonized Ramos cells. For interaction peaks that represent
minor binding fractions this is less or not at all visible as the
information contained in the binding traces is not sufficient to
capture the exact shape of the interaction peak. Both
InteractionMap peaks thus presumably represent multivalent
binding of C1q to cell-bound IgG Fc-domains. The strong
interaction component likely represents binding of C1q to IgG
hexamers, whereas the less stable interaction component likely
represents binding of C1q to IgG-Fc multimers that are smaller
than hexamers, which have been shown to result in some CDC
activity (24, 36). A general fast association for C1q is in
agreement with previous reports and also explains the fast on-
set of CDC, reaching maximum killing levels within 10 min even
at C1q concentrations as low as 1 µg/ml (21, 38). The apparent
affinity for C1q binding to OFA coated Daudi cells, as
determined with an end-point assay, has been reported
previously to be 16 nM (21, 38, 59), which is close to the value
reported here for the less stable interaction component. Data
resolution for end-point affinity measurements is typically not
sufficient to discriminate between individual interaction
components with different affinities. Of note, the C1q binding
assay set-up in this study does not capture binding to IgG-Fc
monomers, as binding is only detected if C1q concentrations are
getting closer to the affinity value of the interaction, i.e., around
10–100 µM for binding to Fc monomers (39) which might
explain the lack of binding observed for OBI.
Regarding the functional consequences of C1q binding to mAb
opsonized target B cells, we systematically compared complement
mediated cell killing by RTX, OFA and OBI on human lymphoma
cell lines and humanprimary B cells differing in expression levels ofFrontiers in Immunology | www.frontiersin.org 13CD20 and complement regulatory proteins. Similar to what was
previously reported (52), Ramos cells proved to be extremely
sensitive in this assay as all three mAbs, and to a lesser extent
serum in absence of anti-CD20 IgG, are able to significantly induce
complement-dependent cell death. A potential explanation for
Ramos cells being very sensitive to CDC is the strong C1q capture
in combination with the absence of complement regulatory
proteins. Even though LCL1.11 cells also display a strong C1q
capture, CDC sensitivity is clearly reduced compared to Ramos
cells, whichmight be explained by a lower expression of CD20 and
the high expression of bothCD55 andCD59. The low expression of
both complement regulatory proteins might also account for the
rather efficient CDC in Daudi cells, despite having the least strong
C1q capture among the investigated cell lines. Surprisingly, P493.6
cells which strongly express CD20 and also nicely captureC1qwere
quite resistant to CDC induction supporting the notion that
expression levels of complement regulatory proteins rather than
CD20 determine the efficacy of complement-dependent killing of B
cell lines. A decreased susceptibility for CDC and complement
activation in general could also be observed for freshly isolated
primary human B cells despite levels of CD20 and CD59 that are
comparable to Ramos and Daudi. Elevated expression levels of
CD55 on primary B cells might instead explain reduced
complement activation. In fact, only OFA was able to consistently
kill primary B cells as well as CLL B cells in a complement-
dependent manner, again confirming the superior capacity of
complement activation. In any case, the data presented here
suggests that the choice of the in vitro model system and
especially target B cell can dramatically impact conclusions about
the extent of complement activation induced by CD20-specific
mAbs. Given the contradictory literature (6, 56, 60–63), it thereforeA B
C
FIGURE 7 | Complement dependent lysis and C3b deposition on primary human B cells. CDC and C3b deposition were compared for primary human B cells
derived from healthy donor blood upon treatment with 20 µg/ml Rituximab (RTX), Ofatumumab (OFA), or Obinutuzumab (OBI) in absence (white) or presence of 20%
human serum (NHS, black bars) or heat-inactivated serum (HIS, gray bars) for 30 min at 37°C. (A) Exemplary dot plots of CD19 and DAPI staining. (B) Quantification
of living CD19+DAPI- cells. (C) Quantification of C3b/iC3b deposition on B cells. Bars show mean and standard deviation of n=4 independent experiments using
PBMCs from different donors and treated with four human sera each. For statistical analysis, two-way ANOVA and Sidak´s multiple comparison test were applied.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.January 2021 | Volume 11 | Article 609941
Bondza et al. Complement Activation by CD20 mAbsstill remains to be seen whether CD20, complement regulator
expression levels or a combination of both ultimately determine
target cell susceptibility for complementdependent inductionof cell
death. Regarding the observed increase of CD19- cells in CLL
samples upon OBI (and to a lesser extent RTX) treatment, we
speculate that OBImight induce a down-regulation of CD19 as has
been previously described for RTX (57, 58). To the best of ourFrontiers in Immunology | www.frontiersin.org 14knowledge this has not been observed before for OBI but data by
Reddy et al. suggest that this might indeed be the case (29).
However, the specifics of this potential reduction in CD19 would
need to be investigated in more detail. One factor affecting our
observations could be the short incubation time of only 30 min in
this study which might enable capturing transitional effects during




FIGURE 8 | Complement dependent lysis and C3b deposition on primary human chronic lymphocytic leukemia (CLL) B cells. Complement-dependent cytotoxicity
(CDC) and C3b deposition were compared for primary human B cells derived from CLL patients with distinct expression profiles of CD20 and CD59 upon treatment
with 20 µg/ml Rituximab (RTX), Ofatumumab (OFA), or Obinutuzumab (OBI) in absence (white) or presence of 20% normal (NHS, black) or heat-inactivated (HIS,
gray) human serum for 30 min at 37°C. (A) Flow cytometry expression analysis of CD19 and CD20, FcgRIIb, CD55, and CD59 on CD19+ cells of healthy (HD) or CLL
B cells. (B) Exemplary dot plots of CD19 and DAPI staining. (C) Quantification of living CD19+DAPI- cells for three to four sera. (D) Quantification of C3b/iC3b
deposition on CD19+ cells. Bars show mean ± standard deviation of three to four serum samples. For statistical analysis, Mann Whitney test (A) or two-way ANOVA
and Sidak´s multiple comparison test (C, D) were applied. *p<0.05, **p<0.01, ****p<0.0001.January 2021 | Volume 11 | Article 609941
Bondza et al. Complement Activation by CD20 mAbsThere is accumulating evidence that efficiency of CDC
induction by mAbs is dependent on a range of factors, such as
the binding epitope and binding orientation of the mAb, as well as
the antibody elbow hinge angle (30–33). This complexity is difficult
tomimicwhenmeasuringC1q binding in artificial, isolated protein
systems, especially since antigen mobility in the membrane might
play a role (36). For anti-EGFR mAbs it has been shown that
monovalent target engagement results in higher CDC efficacy. This
could be a consequence of monovalent binding resulting in a
higher number of IgGs bound and this, in turn, might increase the
likelihood for the formation of multimeric IgG-Fc platforms
suitable for C1q binding (37). For anti-CD20 mAbs, on the other
hand, bivalent binding might enhance crosslinking of CD20 and
thus lead to more efficient clustering of CD20 and bound mAbs.
This notion is supported by recent structural studies showing that
for RTX and OFA two Fabs belonging to different antibody
molecules can interact with the same CD20 dimer. In contrast,
only one Fab of the type IImAbOBI can be bound per CD20 dimer
due to sterical constraints. As a consequence, it was suggested that
type I mAbs can act as molecular seeds that promote the
concatenation of IgG and CD20 molecules into larger molecular
assemblies (25, 64). In linewith this, it was previously observed that
binding of type I anti-CD20mAbs causes segregation of CD20 into
detergent-resistant membrane domains which facilitates CDC
induction (22). One could therefore speculate that the differences
observed between the lymphoma cell lines and primary B cells
could be caused by specific plasma membrane compositions
resulting in differential distribution and mobility of CD20 and
subsequently enhanced or decreased capture by anti-CD20 mAbs.
Indeed, we identified low levels of sphingomyelin GM1, a typical
component of organized membrane domains, in complement-
resistant P493.6 cells while GM1 was highly present in the
membrane of highly susceptible Ramos cells (Supplementary
Figure 10). This suggests that Ramos cells have more organized
microdomains with potentially pre-clustered CD20. Consequently,
bivalent target engagement, IgG crosslinking and thereby the
formation of suitable platforms for C1q capture may be
facilitated. It should also be noted that GM1 levels in all tested
cell lines were higher than in human primary cells.
One can further speculate that antibody induced clustering is
more efficient in promoting IgG-Fc arrangements for C1q binding
than increasing the total numberofboundIgG that is not in clusters.
This would explainwhymultivalent C1q binding to cells opsonized
with the type I mAbs OFA and RTX, whose binding can act as
molecular seeds and induces clustering of CD20, could be detected
(22, 25). In contrast, no strong interaction of C1q was seen on cells
opsonized with OBI, which binds CD20 dimers in a terminal
conformation that does not allow the concatenation of several
CD20 dimers into larger clusters (25). Differences in membrane
mobility andmAbmediated clustering could also explainwhy type I
anti-CD20mAbs generally induce CDCmore efficiently than anti-
EGFRmAbs.Whetherbivalentormonovalent target engagement is
preferable for C1q binding might thus very well depend on the
lateral receptor mobility in the cell membrane that may ormay not
be influenced by binding of the mAb. Interestingly, it has been
reported that (Fab)2 fragments of type I anti-CD20 mAbs canFrontiers in Immunology | www.frontiersin.org 15activate complement in a C1q dependent manner (65). This
suggests that other factors than IgG-Fc arrangement contribute to
cell lysis by CDC for B cells, further strengthening the notion that
complement activation is complex and conditions for optimalCDC
activity may vary between target surface molecules.DATA AVAILABILITY STATEMENT
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